Clinical Trials Logo
  1. Home
  2. Severe Sepsis
  3. NCT00484146
  4. Details
NCT00484146 Clinical Trial

Alterations of Immunologic Mediators During Severe Sepsis

Severe Sepsis Clinical Trial

— LAVISS_01  

Official title:
Alterations of Immunologic Mediators During Severe Sepsis

Clinical Trial Details — Status: Terminated

Administrative data
NCT number NCT00484146
Other study ID # ISRCTN34508816
Secondary ID ISRCTN34508816
Status Terminated
Phase N/A
First received June 7, 2007
Last updated February 7, 2017
Start date June 2006
Est. completion date December 2012

Study information
Verified date February 2017
Source Klinikum St. Georg gGmbH
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Severe sepsis induces significant changes in expression of insulin- and toll-like receptors, cytokines, markers of apoptosis, and activation of t- and b-lymphocytes.

Description:

In patients at early stage of severe sepsis, we investigate the expression of pro- and anti-inflammatory cytokines, chemokines, adhesion-molecules, toll-like receptors, insulin-receptors, markers of apoptosis und of t- and b-cell-activation on a mRNA level.

Recruitment information / eligibility
Status Terminated
Enrollment 20
Est. completion date December 2012
Est. primary completion date December 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- age >= 18 y

- agreement with study procedures

- 3 of 4 SIRS-criteria

- proven or highly suspected infection

- 2 or more sepsis-induced organ failures

- start of first sepsis-induced organ failure within the last 36 hours

Exclusion Criteria:

- non-agreement with study procedures

- signs of severe sepsis with organ failure > 36 hours

- chronic immuno-compromising diseases

- chronic therapy with anti-inflammatory drugs

- non-curable cancer

- chronic renal failure with hemodialysis

- pregnancy or breast-feeding

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Germany Klinikum St. Georg gGmbH, Interdisciplinary Intensive Care Unit Leipzig Sachsen

Sponsors (2)
Lead Sponsor Collaborator
Klinikum St. Georg gGmbH University of Halle Medical Faculty

Country where clinical trial is conducted

Germany, 

Outcome
Type Measure Description Time frame Safety issue
Primary severity of sepsis SOFA-Score 96 hours after diagnosis of sepsis
See also
  Status Clinical Trial Phase
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Recruiting NCT02899143 - Short-course Antimicrobial Therapy in Sepsis Phase 2
Completed NCT02539147 - Characterization of Non-canonical Way in Inflammasome Monocytes of Patients With Severe Sepsis N/A
Completed NCT01932814 - Acute Kidney Injury in Septic Critically Ill Patients : Are Aminoglycosides Really Harmful? N/A
Completed NCT01929772 - German Lactat Clearance in Severe Sepsis N/A
Completed NCT01449721 - Preemptive Resuscitation for Eradication of Septic Shock N/A
Active, not recruiting NCT01162109 - Zinc Therapy in Critical Illness Phase 1
Not yet recruiting NCT01211899 - 4G/5G Polymorphism of Plasminogen Activator Inhibitor-1 Gene and Disseminated Intravascular Coagulation in Severe Sepsis and Septic Shock N/A
Completed NCT00934011 - Use of Inflammatory Biomarkers to Guide Antibiotic Therapy in Patients With Severe Infections N/A
Recruiting NCT00335907 - Protocol-driven Hemodynamic Support for Patients With Septic Shock N/A
Completed NCT00463645 - Investigation of Correlation Between Interstitial and Arterial Blood Glucose Concentrations in Septic Patients N/A
Completed NCT02361528 - GM-CSF to Decrease ICU Acquired Infections Phase 3
Completed NCT02734550 - (1,3)-β-D-glucan Based Diagnosis of Invasive Candida Infection in Sepsis N/A
Completed NCT02973243 - The Vital Signs to Identify, Target, and Assess Level (VITAL) Care Study III N/A
Terminated NCT03895853 - Early Metabolic Resuscitation for Septic Shock Phase 2
Completed NCT01945983 - Early Use of Norepinephrine in Septic Shock Resuscitation N/A
Completed NCT01598831 - Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy Phase 3
Enrolling by invitation NCT02258984 - Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial N/A